XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapyAndreas Engert, Auro del Giglio, Laimonas Griškevičius et al.|Leukemia & lymphoma/Leukemia and lymphoma|2009Cited by 76